Akari's Nomacopan reduces skin inflammation in Phase II

Akari said initial data from three patients with bullous pemphigoid in a Phase II trial showed Nomacopan (Coversin) reduced symptoms of the orphan skin disease.

Akari Therapeutics plc (NASDAQ:AKTX) said Nomacopan reduced BP Disease Area Index (BPDAI) score by 52% from baseline at day 42...